Cargando…

Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation

BACKGROUND: Perturbing Hsp90 chaperone function targets hypoxia inducible factor (HIF) function in a von Hippel-Lindau (VHL) independent manner, and represents an approach to combat the contribution of HIF to cell renal carcinoma (CCRCC) progression. However, clinical trials with the prototypic Hsp9...

Descripción completa

Detalles Bibliográficos
Autores principales: Bohonowych, Jessica ES, Peng, Shuping, Gopal, Udhayakumar, Hance, Michael W, Wing, Shane B, Argraves, Kelley M, Lundgren, Karen, Isaacs, Jennifer S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259130/
https://www.ncbi.nlm.nih.gov/pubmed/22172030
http://dx.doi.org/10.1186/1471-2407-11-520
_version_ 1782221350264373248
author Bohonowych, Jessica ES
Peng, Shuping
Gopal, Udhayakumar
Hance, Michael W
Wing, Shane B
Argraves, Kelley M
Lundgren, Karen
Isaacs, Jennifer S
author_facet Bohonowych, Jessica ES
Peng, Shuping
Gopal, Udhayakumar
Hance, Michael W
Wing, Shane B
Argraves, Kelley M
Lundgren, Karen
Isaacs, Jennifer S
author_sort Bohonowych, Jessica ES
collection PubMed
description BACKGROUND: Perturbing Hsp90 chaperone function targets hypoxia inducible factor (HIF) function in a von Hippel-Lindau (VHL) independent manner, and represents an approach to combat the contribution of HIF to cell renal carcinoma (CCRCC) progression. However, clinical trials with the prototypic Hsp90 inhibitor 17-AAG have been unsuccessful in halting the progression of advanced CCRCC. METHODS: Here we evaluated a novel next generation small molecule Hsp90 inhibitor, EC154, against HIF isoforms and HIF-driven molecular and functional endpoints. The effects of EC154 were compared to those of the prototypic Hsp90 inhibitor 17-AAG and the histone deacetylase (HDAC) inhibitor LBH589. RESULTS: The findings indicate that EC154 is a potent inhibitor of HIF, effective at doses 10-fold lower than 17-AAG. While EC154, 17-AAG and the histone deacetylase (HDAC) inhibitor LBH589 impaired HIF transcriptional activity, CCRCC cell motility, and angiogenesis; these effects did not correlate with their ability to diminish HIF protein expression. Further, our results illustrate the complexity of HIF targeting, in that although these agents suppressed HIF transcripts with differential dynamics, these effects were not predictive of drug efficacy in other relevant assays. CONCLUSIONS: We provide evidence for EC154 targeting of HIF in CCRCC and for LBH589 acting as a suppressor of both HIF-1 and HIF-2 activity. We also demonstrate that 17-AAG and EC154, but not LBH589, can restore endothelial barrier function, highlighting a potentially new clinical application for Hsp90 inhibitors. Finally, given the discordance between HIF activity and protein expression, we conclude that HIF expression is not a reliable surrogate for HIF activity. Taken together, our findings emphasize the need to incorporate an integrated approach in evaluating Hsp90 inhibitors within the context of HIF suppression.
format Online
Article
Text
id pubmed-3259130
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32591302012-01-18 Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation Bohonowych, Jessica ES Peng, Shuping Gopal, Udhayakumar Hance, Michael W Wing, Shane B Argraves, Kelley M Lundgren, Karen Isaacs, Jennifer S BMC Cancer Research Article BACKGROUND: Perturbing Hsp90 chaperone function targets hypoxia inducible factor (HIF) function in a von Hippel-Lindau (VHL) independent manner, and represents an approach to combat the contribution of HIF to cell renal carcinoma (CCRCC) progression. However, clinical trials with the prototypic Hsp90 inhibitor 17-AAG have been unsuccessful in halting the progression of advanced CCRCC. METHODS: Here we evaluated a novel next generation small molecule Hsp90 inhibitor, EC154, against HIF isoforms and HIF-driven molecular and functional endpoints. The effects of EC154 were compared to those of the prototypic Hsp90 inhibitor 17-AAG and the histone deacetylase (HDAC) inhibitor LBH589. RESULTS: The findings indicate that EC154 is a potent inhibitor of HIF, effective at doses 10-fold lower than 17-AAG. While EC154, 17-AAG and the histone deacetylase (HDAC) inhibitor LBH589 impaired HIF transcriptional activity, CCRCC cell motility, and angiogenesis; these effects did not correlate with their ability to diminish HIF protein expression. Further, our results illustrate the complexity of HIF targeting, in that although these agents suppressed HIF transcripts with differential dynamics, these effects were not predictive of drug efficacy in other relevant assays. CONCLUSIONS: We provide evidence for EC154 targeting of HIF in CCRCC and for LBH589 acting as a suppressor of both HIF-1 and HIF-2 activity. We also demonstrate that 17-AAG and EC154, but not LBH589, can restore endothelial barrier function, highlighting a potentially new clinical application for Hsp90 inhibitors. Finally, given the discordance between HIF activity and protein expression, we conclude that HIF expression is not a reliable surrogate for HIF activity. Taken together, our findings emphasize the need to incorporate an integrated approach in evaluating Hsp90 inhibitors within the context of HIF suppression. BioMed Central 2011-12-15 /pmc/articles/PMC3259130/ /pubmed/22172030 http://dx.doi.org/10.1186/1471-2407-11-520 Text en Copyright ©2011 Bohonowych et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bohonowych, Jessica ES
Peng, Shuping
Gopal, Udhayakumar
Hance, Michael W
Wing, Shane B
Argraves, Kelley M
Lundgren, Karen
Isaacs, Jennifer S
Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation
title Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation
title_full Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation
title_fullStr Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation
title_full_unstemmed Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation
title_short Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation
title_sort comparative analysis of novel and conventional hsp90 inhibitors on hif activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259130/
https://www.ncbi.nlm.nih.gov/pubmed/22172030
http://dx.doi.org/10.1186/1471-2407-11-520
work_keys_str_mv AT bohonowychjessicaes comparativeanalysisofnovelandconventionalhsp90inhibitorsonhifactivityandangiogenicpotentialinclearcellrenalcellcarcinomaimplicationsforclinicalevaluation
AT pengshuping comparativeanalysisofnovelandconventionalhsp90inhibitorsonhifactivityandangiogenicpotentialinclearcellrenalcellcarcinomaimplicationsforclinicalevaluation
AT gopaludhayakumar comparativeanalysisofnovelandconventionalhsp90inhibitorsonhifactivityandangiogenicpotentialinclearcellrenalcellcarcinomaimplicationsforclinicalevaluation
AT hancemichaelw comparativeanalysisofnovelandconventionalhsp90inhibitorsonhifactivityandangiogenicpotentialinclearcellrenalcellcarcinomaimplicationsforclinicalevaluation
AT wingshaneb comparativeanalysisofnovelandconventionalhsp90inhibitorsonhifactivityandangiogenicpotentialinclearcellrenalcellcarcinomaimplicationsforclinicalevaluation
AT argraveskelleym comparativeanalysisofnovelandconventionalhsp90inhibitorsonhifactivityandangiogenicpotentialinclearcellrenalcellcarcinomaimplicationsforclinicalevaluation
AT lundgrenkaren comparativeanalysisofnovelandconventionalhsp90inhibitorsonhifactivityandangiogenicpotentialinclearcellrenalcellcarcinomaimplicationsforclinicalevaluation
AT isaacsjennifers comparativeanalysisofnovelandconventionalhsp90inhibitorsonhifactivityandangiogenicpotentialinclearcellrenalcellcarcinomaimplicationsforclinicalevaluation